440 related articles for article (PubMed ID: 27479789)
21. Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI.
Arnfield EG; Tam L; Pattison DA; Younger J; Chikatamarla VA; Wyld D; Burge M; McCormack L; Ladwa R; Ramsay S
J Nucl Cardiol; 2023 Dec; 30(6):2676-2691. PubMed ID: 37587328
[TBL] [Abstract][Full Text] [Related]
22.
Hope TA; Calais J; Zhang L; Dieckmann W; Millo C
J Nucl Med; 2019 Sep; 60(9):1266-1269. PubMed ID: 30850506
[TBL] [Abstract][Full Text] [Related]
23. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
[TBL] [Abstract][Full Text] [Related]
24. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.
Bombardieri E; Coliva A; Maccauro M; Seregni E; Orunesu E; Chiti A; Lucignani G
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):3-15. PubMed ID: 20168282
[TBL] [Abstract][Full Text] [Related]
25. The radionuclide molecular imaging and therapy of neuroendocrine tumors.
Li S; Beheshti M
Curr Cancer Drug Targets; 2005 Mar; 5(2):139-48. PubMed ID: 15810878
[TBL] [Abstract][Full Text] [Related]
26. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Hicks RJ
Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
[TBL] [Abstract][Full Text] [Related]
28.
Briganti V; Cuccurullo V; Berti V; Di Stasio GD; Linguanti F; Mungai F; Mansi L
Curr Radiopharm; 2020; 13(3):166-176. PubMed ID: 31886756
[TBL] [Abstract][Full Text] [Related]
29. Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.
Toumpanakis C; Kim MK; Rinke A; Bergestuen DS; Thirlwell C; Khan MS; Salazar R; Oberg K
Neuroendocrinology; 2014; 99(2):63-74. PubMed ID: 24458014
[TBL] [Abstract][Full Text] [Related]
30. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Kjaer A; Knigge U
Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
[TBL] [Abstract][Full Text] [Related]
31. Nuclear imaging of neuroendocrine tumours.
Sundin A; Garske U; Orlefors H
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
[TBL] [Abstract][Full Text] [Related]
32. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
33. State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging.
Carollo A; Papi S; Grana CM; Mansi L; Chinol M
Curr Radiopharm; 2019; 12(2):107-125. PubMed ID: 30843499
[TBL] [Abstract][Full Text] [Related]
34. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.
Hindié E
Theranostics; 2017; 7(5):1159-1163. PubMed ID: 28435455
[TBL] [Abstract][Full Text] [Related]
35. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
36. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.
Baum RP; Kulkarni HR; Carreras C
Semin Nucl Med; 2012 May; 42(3):190-207. PubMed ID: 22475428
[TBL] [Abstract][Full Text] [Related]
37. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589
[TBL] [Abstract][Full Text] [Related]
38. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.
Fortunati E; Argalia G; Zanoni L; Fanti S; Ambrosini V
Curr Treat Options Oncol; 2022 May; 23(5):703-720. PubMed ID: 35325412
[TBL] [Abstract][Full Text] [Related]
39. PET/MRI imaging in neuroendocrine neoplasm.
Virarkar MK; Montanarella M; Itani M; Calimano-Ramirez L; Gopireddy D; Bhosale P
Abdom Radiol (NY); 2023 Dec; 48(12):3585-3600. PubMed ID: 36525051
[TBL] [Abstract][Full Text] [Related]
40. Imaging of NETs with PET radiopharmaceuticals.
Ambrosini V; Tomassetti P; Franchi R; Fanti S
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):16-23. PubMed ID: 20168283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
